Lyme Disease Vaccine Market Report 2026

The lyme disease vaccine market size has grown strongly in recent years. It will grow from $1.12 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of lyme disease in endemic regions, historical limitations of antibiotic-only treatment approaches, early-stage vaccine research initiatives, growing awareness of tick-borne infections, public health surveillance improvements.

The lyme disease vaccine market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to expansion of vaccination programs in endemic areas, increasing investment in infectious disease prevention, advancement of next-generation vaccine platforms, rising adoption of combination vaccines, growing global focus on zoonotic disease control. Major trends in the forecast period include advancement of recombinant vaccine technologies, increased focus on preventive immunization programs, expansion of clinical research for tick-borne diseases, growing emphasis on long-lasting immunity solutions, rising collaboration between public and private health organizations.

The rising prevalence of Lyme disease is expected to drive the growth of the Lyme disease vaccine market in the coming years. Lyme disease is a tick-borne infection caused by Borrelia bacteria, resulting in fever, fatigue, rash, and potentially severe joint, heart, or nerve complications if left untreated. The increasing occurrence of Lyme disease is linked to climate change, as warmer temperatures and milder winters expand tick habitats, raising human exposure to infected ticks. Lyme disease vaccines help prevent infection by training the immune system to identify and combat Borrelia bacteria, lowering the risk of disease. They also simplify disease management by offering long-term protection, thereby enhancing public health outcomes. For example, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal health agency, around 89,000 cases of Lyme disease were reported in the United States in 2023, while other estimates suggest that roughly 476,000 people may be diagnosed and treated for Lyme disease annually. Consequently, the increasing prevalence of Lyme disease is contributing to the expansion of the Lyme disease vaccine market.

The increasing healthcare expenditure is expected to drive the growth of the Lyme disease vaccine market in the coming years. Healthcare expenditure refers to the total funds allocated to medical services, treatments, facilities, research, and public health initiatives aimed at maintaining or improving health outcomes. The rising demand for healthcare expenditure is driven by the growing prevalence of chronic diseases, which require long-term and costly treatments. Higher healthcare expenditure supports Lyme disease vaccine development by providing greater funding for research and clinical trials, accelerating innovation and production. It facilitates advanced vaccine technologies, enhancing accessibility and effectiveness for at-risk populations. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the rising healthcare expenditure is contributing to the growth of the Lyme disease vaccine market.

Major companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, including booster vaccines, to address unmet medical needs, improve immune protection, and simplify vaccination schedules. Booster vaccines are additional doses administered after the initial vaccination to restore or enhance long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, announced positive immunogenicity and safety results from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This multivalent vaccine stimulates the immune system to generate antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies neutralize the bacteria inside the tick, preventing infection in humans. The robust immune response and favorable safety profile observed after a third booster dose were consistent with those seen following previous annual booster doses, further supporting compatibility with the expected advantages of a yearly vaccination before each Lyme season. This booster approach aims to provide ongoing protection against Lyme disease, highlighting the potential for an annual pre-season booster to simplify prevention for individuals at risk.

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lyme disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the lyme disease vaccine market by increasing costs of imported biological raw materials, adjuvants, laboratory reagents, cold-chain equipment, and specialized manufacturing components. North America and Europe are most affected due to dependence on cross-border biopharmaceutical supply chains, while emerging regions face higher vaccine procurement costs. These tariffs are increasing production expenses and extending development timelines. However, they are also supporting domestic vaccine manufacturing initiatives, encouraging regional research collaborations, and strengthening localized biopharmaceutical supply capabilities.

The lyme disease vaccine market research report is one of a series of new reports that provides lyme disease vaccine market statistics, including lyme disease vaccine industry global market size, regional shares, competitors with a lyme disease vaccine market share, detailed lyme disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the lyme disease vaccine industry. This lyme disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A Lyme disease vaccine refers to a biological preparation developed to activate the immune system to identify and combat Borrelia burgdorferi, the bacterium that causes Lyme disease, thereby helping to prevent infection after a tick bite. These vaccines function by inducing the production of targeted antibodies that inactivate the bacteria, lowering the likelihood of disease transmission and related complications, and act as a vital measure for managing Lyme disease in regions where it is endemic.

The primary vaccine types for Lyme disease include recombinant vaccines, subunit vaccines, live attenuated vaccines, and others. Recombinant vaccines are developed using genetic engineering methods to produce specific proteins (antigens) derived from Borrelia burgdorferi, the bacterium responsible for Lyme disease. These vaccines make use of various technologies such as the lymphocytic transformation test, urine antigen testing, immunofluorescent staining, nucleic acid testing, and serological testing, and are designed for different age groups including pediatric, adult, and geriatric populations. They are distributed through multiple channels, including hospitals and clinics, pharmacies, government supply systems, and others, and are used by end users such as hospitals, clinical laboratories, and others.

The Lyme disease vaccine market consists of sales of pre-filled syringes, single or multi-dose vials, vaccine kits, storage and delivery equipment, and cold-chain packaging materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.